cobicistat, atazanavir - Výsledky vyhľadávania

Európska únia - chorvátčina - EMA (European Medicines Agency)

prezista

janssen-cilag international nv - danmavir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Bosna a Hercegovina - chorvátčina - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pdsolone 40 mg 40 mg/1 bočica prašak za rastvor za injekciju

rhei life d.o.o. bijeljina - metilprednizolon - prašak za rastvor za injekciju - 40 mg/1 bočica - 1 bočica s praškom za injekciju sadrži: 40 mg metilprednizolona

Európska únia - chorvátčina - EMA (European Medicines Agency)

genvoya

gilead sciences ireland uc - элвитегравир, кобицистат, эмтрицитабин, Тенофовир alafenamide - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - genvoya je indiciran za liječenje odraslih i adolescenata (u dobi od 12 godina i stariji sa tjelesne težine najmanje 35 kg) zaraženih virusom humane imunodeficijencije (hiv-a 1) 1 bez bilo koje poznate mutacija povezanih s rezistencijom na inhibitora integraze, emtricitabin ili tenofovir.

Európska únia - chorvátčina - EMA (European Medicines Agency)

rezolsta

janssen-cilag international n.v. - дарунавир, кобицистат - hiv infekcije - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta, indicirana je u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje infekcije virusom humane imunodeficijencije 1 (hiv 1) u odraslih osoba starijih od 18 godina. Генотипическое testiranje trebali bi se rukovoditi pri korištenju rezolsta.

Európska únia - chorvátčina - EMA (European Medicines Agency)

symtuza

janssen-cilag international nv - дарунавир, кобицистат, эмтрицитабин, Тенофовир alafenamide - hiv infekcije - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza je indiciran za liječenje humane imunodeficijencije tip 1 (hiv‑1) infekcija u odraslih i adolescenata (u dobi od 12 godina i stariji sa tijela težina najmanje 40 kg). genotypic testing should guide the use of symtuza.

flixonase 50 µg/1 doza sprej za nos, suspenzija

evropa lijek pharma d.o.o. - flutikazon - sprej za nos, suspenzija - 50 µg/1 doza - 1 doza spreja za nos, suspenzije sadrži: 50 mcg flutikazon propionata

sabacomb 250 µg/1 doza+ 100 µg/1 doza stlačeni inhalat, suspenzija

providens d.o.o. sarajevo - Беклометазон, salbutamol - stlačeni inhalat, suspenzija - 250 µg/1 doza+ 100 µg/1 doza - 1 doza sadrži: 250 µg beklometazona 100 µg salbutamola

dexason 4 mg/1 ml rastvor za injekciju

galenika d.o.o. - дексаметазон - rastvor za injekciju - 4 mg/1 ml - 1 ml rastvora za injekciju sadrži: 4 mg deksametazon fosfata (u obliku deksametazon natrijum fosfata)

foster nexthaler 100 µg/1 doza+ 6 µg/1 doza prašak za inhaliranje

providens d.o.o. sarajevo - Беклометазон, formoterol - prašak za inhaliranje - 100 µg/1 doza+ 6 µg/1 doza - 1 doza praška za inhaliranje sadrži: 100 µg beklometazon dipropionat, anhidrid 6 µg formoterol fumarat dihidrat

flixonase 50 µg/1 doza sprej za nos, suspenzija

evropa lijek pharma d.o.o. - flutikazon - sprej za nos, suspenzija - 50 µg/1 doza - 1 doza spreja za nos, suspenzije sadrži: 50 mcg flutikazon propionata